COMMUNIQUÉS West-GlobeNewswire
-
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
24/11/2025 -
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
24/11/2025 -
Cerevance to Highlight Potential of Solengepras in Parkinson’s Disease at the 2025 Parkinson Study Group Annual Meeting
24/11/2025 -
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
24/11/2025 -
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
24/11/2025 -
Neuphoria Therapeutics Inc. Sends Letter to Stockholders
24/11/2025 -
Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates
24/11/2025 -
ProMIS Neurosciences Announces Reverse Stock Split
24/11/2025 -
Annovis Announces Two Presentations at the CTAD 2025 Conference
24/11/2025 -
Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers
24/11/2025 -
DXS INTERNATIONAL PLC (AQSE: DXSP): Notice of 2025 Annual General Meeting
24/11/2025 -
Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
24/11/2025 -
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
24/11/2025 -
BioPorto A/S raises approximately DKK 43 million in new capital round - Change in number of shares and votes
24/11/2025 -
Managers’ transactions
24/11/2025 -
Nanox Announces $15 Million Registered Direct Offering of Common Stock
24/11/2025 -
Sequana Medical Announces First U.S. Commercial alfapump® Implantation at Mount Sinai Hospital in New York
24/11/2025 -
Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary and announces key developments for its North American business
24/11/2025 -
ONWARD Medical Drives Strong US ARC-EX Adoption and Achieves Important Scientific and Regulatory Milestones in Q3 2025
24/11/2025
Pages